EGFR and breast carcinoma: In contrast to mTOR canonical inhibitors, treatment of ErbB2 breast cancer by MEDICA allows for both, inhibition of mTORC1 activity while concomitantly disrupting ErbB family members and their signaling cascades (Figs. 4a–c and 6a).